e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

11.06 -0.26 (-2.30%)

Streaming Delayed Price Updated: 2:11 PM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Is It Too Late to Buy Intellia Therapeutics? ↗

July 10, 2021

After skyrocketing 68% last week, will this stock keep running higher?

Via The Motley Fool

Here's Why Regeneron Gained 11% Last Month ↗

July 07, 2021

The biopharma outfit dropped news that may mean more for the medicine industry than anybody fully understands.

Via The Motley Fool

2 Reasons to Buy Intellia -- and 1 Big Reason Why I Won't ↗

July 04, 2021

After the clinical-stage biotech publicized promising data for its gene-editing treatment of a rare and fatal disease, its stock skyrocketed.

Via The Motley Fool

Stock Market Rally: S&P 500, Nasdaq Hit Highs; Facebook, Tesla, Nio, Intellia, Didi IPO, OPEC+ In Focus ↗

July 02, 2021

The S&P 500 and Nasdaq hit record highs last week. Facebook hit a $1 trillion market cap. Tesla deliveries jumped.

Via Investor's Business Daily

Topics Initial Public Offering Stocks

Analyst Ratings For Intellia Therapeutics ↗

June 29, 2021

Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA

Via Benzinga

Here's What Drove Gene Editing Stocks Higher This Week ↗

July 02, 2021

The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.

Via The Motley Fool

The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts ↗

July 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE...

Via Benzinga

5 Reasons Alnylam's Still a Top Biotech Stock to Buy Now ↗

July 01, 2021

Despite a threat from Intellia on the horizon, Alnylam's still in a position to deliver big gains for patient investors.

Via The Motley Fool

Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders ↗

July 01, 2021

Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven...

Via Benzinga

72 Biggest Movers From Yesterday ↗

July 01, 2021

Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN...

Via Benzinga

Topics Initial Public Offering

'Halftime Report' Traders Share Their Thoughts On Crispr Therapeutics And Bed Bath & Beyond ↗

June 30, 2021

Amy Raskin said on CNBC's "Fast Money Halftime Report" that she would hold Crispr Therapeutics AG (NASDAQ: CRSP). She doesn't own the stock, but she owns...

Via Benzinga

Why Intellia Therapeutics Was a Winner on Wednesday ↗

June 30, 2021

The company is about to fatten its coffers significantly.

Via The Motley Fool

In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC ↗

June 30, 2021

Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body. What Happened: On Monday,...

Via Benzinga

Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar ↗

June 30, 2021

Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia.

Via InvestorPlace

Why Gene Editing Stocks Are Trading Higher Again Today ↗

June 30, 2021

Shares of gene editing stocks are continuing higher in sympathy with peer company Intellia (NASDAQ: NTLA), which gained in recent sessions following positive data for its...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

June 30, 2021

Gainers Dare Bioscience (NASDAQ:DARE) stock moved upwards by 26.82% to $2.08 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume...

Via Benzinga

51 Stocks Moving In Wednesday's Mid-Day Session ↗

June 30, 2021

Gainers Cuentas Inc. (NASDAQ: CUEN) shares jumped 176.6% to $7.69. The stock spiked following a press release saying "WaveMax to Implement the World's First Shared Wifi6...

Via Benzinga

Unusual Options Activity Insight: Intellia Therapeutics ↗

June 30, 2021

Shares of Intellia Therapeutics (NASDAQ:NTLA) saw some unusual options activity on Wednesday. Following the unusual option alert, the stock price moved up to $183.36. Sentiment...

Via Benzinga

Stocks That Hit 52-Week Highs On Wednesday ↗

June 30, 2021

This morning 132 companies reached new 52-week highs. Noteworthy Mentions: The largest company by market cap to break to a new 52-week high was NVIDIA (NASDAQ:NVDA...

Via Benzinga

The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs ↗

June 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ...

Via Benzinga

Intellia Therapeutics Stock Moves Higher After Capital Raise Of $600M Issued At $145/Share ↗

June 30, 2021

Intellia Therapeutics Inc (NASDAQ: NTLA) has priced a previously announced public offering at $145 per share, representing a discount of 4.4% from the last close...

Via Benzinga

Can Intellia Therapeutics Turn Exciting Trial Results into Profits? ↗

June 30, 2021

New proof-of-concept results are a big deal for the medical community, but what about for your portfolio?

Via The Motley Fool

58 Biggest Movers From Yesterday ↗

June 30, 2021

Gainers BSQUARE Corporation (NASDAQ: BSQR) shares jumped 206.9% to close at $8.04 on Tuesday on abnormally-high volume possibly amid increased attention from retail investors....

Via Benzinga

Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated ↗

June 29, 2021

Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) robust ...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

June 29, 2021

Barclays raised the price target for Skyworks Solutions, Inc. (NASDAQ:

Via Benzinga

Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027

June 29, 2021

Via FinancialNewsMedia

22 Stocks Moving in Tuesday's Pre-Market Session ↗

June 29, 2021

Gainers Exela Technologies, Inc. (NASDAQ: XELA) rose 39% to $2.05 in pre-market trading after gaining over 5% on Monday. Marin Software Incorporated (NASDAQ: MRIN) rose 36.8% to...

Via Benzinga

The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout ↗

June 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,...

Via Benzinga

Intellia Seeks To Raise $400M Via Equity ↗

June 29, 2021

Intellia Therapeutics Inc (NASDAQ: NTLA) commenced an underwritten public offering of $400 million shares of its common stock. Underwriters have an option to...

Via Benzinga

60 Biggest Movers From Yesterday ↗

June 29, 2021

Gainers Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its...

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy